OncoMatch

OncoMatch/Clinical Trials/NCT05972135

Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma

Is NCT05972135 recruiting? Yes, currently enrolling (Sep 2026). This Phase 2 trial studies multiple treatments including Teclistamab and Talquetamab for multiple myeloma.

Phase 2RecruitingSCRI Development Innovations, LLCNCT05972135Data as of Sep 2026

Treatment: Teclistamab · Talquetamab · Tocilizumab · Oral DexamethasoneThis is a phase II study to evaluate the outpatient administration of Teclistamab or Talquetamab in Multiple Myeloma patients

Check if I qualify

Extracted eligibility criteria

Treatments studied

Immunotherapy

TeclistamabTalquetamab

Other

TocilizumabOral Dexamethasone

Cancer type

Multiple Myeloma

Performance status

ECOG 0–1(Restricted strenuous activity)

Prior therapy

Must have received: multiple myeloma therapy

Must have received: multiple myeloma therapy

Lab requirements

Blood counts

grade ≥3 hematologic aes [excluded]

Kidney function

egfr <20 ml/min or is dependent on dialysis [excluded]

Cardiac function

presence of nyha stage iii or iv chf, mi or cabg ≤6 months prior to enrollment, history of clinically significant ventricular arrhythmia or unexplained syncope, severe non-ischemic cardiomyopathy, poorly controlled cad and/or chf, uncontrolled cardiac arrhythmia or clinically significant ecg abnormalities [excluded]

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

  • Oncology Associates of Oregon · Eugene, Oregon
  • TriStar Bone Marrow Transplant · Nashville, Tennessee
  • Vanderbilt- Ingram Cancer Center · Nashville, Tennessee
  • Texas Oncology · Austin, Texas
  • Texas Oncology - San Antonio · San Antonio, Texas

Showing up to 5 US sites.

See all sites on ClinicalTrials.gov →

Frequently asked questions

Is NCT05972135 currently recruiting?

Yes, this trial is currently recruiting patients.

Is prior treatment required for enrollment?

Yes. Patients must have previously received multiple myeloma therapy and multiple myeloma therapy.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify